Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Hansa Biopharma Idefirix PAES Results
Business clinical trial results

Hansa Biopharma Idefirix PAES Results

Analysis based on 6 articles · First reported May 27, 2026 · Last updated May 27, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive clinical trial results for Imlifidase are expected to significantly boost GT Biopharma's stock price and market valuation, as it paves the way for full marketing authorization in Europe. This development also signals potential for broader market access and increased revenue for GT Biopharma, impacting the biotechnology and pharmaceutical sectors positively.

Biotechnology Pharmaceuticals
Event Summary

GT Biopharma announced positive topline results from its European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES) for Imlifidase, a desensitization treatment for highly sensitized kidney transplant patients. The study met its primary objective with 90% one-year graft failure-free survival and demonstrated a safety profile consistent with previous clinical experience. This fulfills a key requirement from the European Union — European Medicines Agency for conditional marketing authorization, and GT Biopharma plans to submit an application for full marketing authorization by the end of 2026. The United States — Food and Drug Administration also accepted the Biologics License Application for imlifidase in February 2026, with a PDUFA action date in December 2026, indicating potential expansion into the US market.

Key Actions
100 GT Biopharma announced positive results
90 GT Biopharma plans to submit application European Union — European Medicines Agency
Entities Involved
stock
GT Biopharma
GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.
Importance 100 Sentiment 75
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency conditionally approved Imlifidase and requested the PAES study, which has now been successfully completed, paving the way for a full marketing authorization application.
Importance 80 Sentiment 50
per
Renée Aguiar-Lucander
As CEO of GT Biopharma, Renée Aguiar-Lucander announced the positive study results and expressed optimism for the full marketing authorization of Imlifidase.
Importance 70 Sentiment 60
per
Tomas Lorant
As the coordinating investigator for the PAES study, Tomas Lorant confirmed the key role of imlifidase in transforming transplantation care for highly sensitized patients.
Importance 60 Sentiment 60
alliance
European Union
The European Union is a key market where Imlifidase is conditionally approved and where the PAES study was conducted, leading to the upcoming application for full marketing authorization.
Importance 60 Sentiment 50
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration accepted the Biologics License Application for imlifidase in February 2026, indicating potential future market expansion for the drug in the US.
Importance 40 Sentiment 50
cnt
United Kingdom
The United Kingdom participated in the PAES study, contributing to the data that supports the efficacy and safety of Imlifidase.
Importance 30 Sentiment 50
cnt
Norway
Imlifidase is conditionally approved in Norway, indicating its broader European market presence.
Importance 20 Sentiment 50
cnt
Liechtenstein
Imlifidase is conditionally approved in Liechtenstein, contributing to its market reach.
Importance 20 Sentiment 50
cnt
Iceland
Imlifidase is conditionally approved in Iceland, expanding its market availability.
Importance 20 Sentiment 50
cnt
Australia
Imlifidase is approved in Australia, demonstrating its global market presence beyond Europe.
Importance 20 Sentiment 50
cnt
Israel
Imlifidase is approved in Israel, further expanding its international market reach.
Importance 20 Sentiment 50
cnt
Switzerland
Imlifidase is approved in Switzerland, indicating its presence in key European markets outside the EU.
Importance 20 Sentiment 50
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.